What are the genetic causes of pheochromocytoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Genetic Causes of Pheochromocytoma

Approximately 30% of pheochromocytomas and paragangliomas (PPGLs) are caused by germline mutations and should be considered hereditary, with several specific genes implicated in their development. 1

Major Hereditary Syndromes Associated with Pheochromocytoma

Classical Syndromes

  • Multiple Endocrine Neoplasia Type 2 (MEN2): Caused by mutations in the RET proto-oncogene, accounting for 5-30% of hereditary pheochromocytomas with 50% penetrance 1
  • Von Hippel-Lindau (VHL) syndrome: Caused by mutations in the VHL gene, representing approximately 13% of hereditary cases with 10-30% penetrance 1
  • Neurofibromatosis Type 1 (NF1): Caused by mutations in the NF1 gene, accounting for about 3% of hereditary cases with 1-6% penetrance 1

Succinate Dehydrogenase (SDHx)-Related Syndromes

  • PGL1: Caused by mutations in SDHD gene (11q23.1), representing 7-10% of hereditary cases with 86% penetrance when paternally inherited (subject to maternal imprinting) 1
  • PGL2: Caused by mutations in SDHAF2 gene (11q12.2), accounting for approximately 1% of cases with 100% penetrance when paternally inherited 1
  • PGL3: Caused by mutations in SDHC gene (1q23.3), representing about 2% of hereditary cases 1
  • PGL4: Caused by mutations in SDHB gene (1p36.13), accounting for 8-10% of hereditary cases with 30% penetrance and highest risk of malignancy 1
  • PGL5: Caused by mutations in SDHA gene (5p15.33), representing approximately 1% of hereditary cases 1

Recently Discovered Susceptibility Genes

  • TMEM127: Located on chromosome 2q11.2, accounting for 1-2% of hereditary cases with 32% penetrance 1
  • MAX: Located on chromosome 14q23.3, representing about 1% of hereditary cases 1
  • FH: Associated with Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), accounting for <1% of cases 1
  • MEN1: Associated with Multiple Endocrine Neoplasia Type 1, representing <1% of cases 1

Rare Genetic Causes

  • BAP1: Associated with tumor predisposition syndrome 1
  • EGLN1/PHD2: Associated with familial erythrocytosis type 3 1
  • EGLN2/PHD1: Rare cause with limited reported cases 1
  • EPAS1/HIF2A: Associated with familial erythrocytosis type 4 1
  • KIF1B: Rare cause with limited reported cases 1
  • KMT2D: Rare cause with limited reported cases 1
  • MDH2: Rare cause with limited reported cases 1

Inheritance Patterns

  • Most hereditary PPGLs show autosomal dominant inheritance, often with reduced penetrance 1
  • Important exception: SDHD and SDHAF2 mutations exhibit maternal imprinting with silencing of the maternal allele, meaning only mutations inherited from the father will cause disease 1

Clinical Implications of Genetic Status

  • SDHB mutation carriers have the highest risk of malignancy and metastatic disease, significantly affecting survival rates 1
  • The 5-year survival rate with metastasized PPGL is only 50-60%, highlighting the importance of early identification 1
  • Patients with hereditary syndromes often develop tumors at younger ages and are more likely to have bilateral, multifocal, or extra-adrenal disease 2

Recommendations for Genetic Testing

  • The American College of Medical Genetics recommends genetic testing consideration for any individual with a personal history of or a first-degree relative with a paraganglioma or pheochromocytoma 1
  • Testing is particularly important for patients with:
    • Family history of PPGL 2
    • Young age at diagnosis 2
    • Bilateral or multifocal disease 2
    • Extra-adrenal tumor location 2
    • Malignant disease 2

Clinical Pitfalls and Caveats

  • Failure to identify a hereditary syndrome can lead to missed opportunities for early detection of other syndrome-associated tumors 2
  • The frequency of germline mutations in apparently sporadic cases is higher than previously thought, approaching 20% 3
  • Genetic testing algorithms should prioritize testing based on clinical presentation, tumor location, and biochemical profile 4
  • Maternal imprinting in SDHD and SDHAF2 means that family history may appear negative if the mutation was inherited from the mother 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management Approach for Pheochromocytoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Pheochromocytoma: the expanding genetic differential diagnosis.

Journal of the National Cancer Institute, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.